Targeting TLR2 to Overcome Autophagy‐Dependent Chemoresistance in Gastric Cancer: Integrating Molecular Docking, Mechanistic Validation, and Therapeutic Evaluation
Journal of Biochemical and Molecular Toxicology · 2026-11 · 40 (11)
DOI: 10.1002/jbt.71137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 11.11.2026. Verfasst von Kuanheng Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery Zone 2, Ningde Clinical Medical College of Fujian Medical University, Ningde City, Fujian, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Autophagy, Drug Resistance, Neoplasm, Molecular Docking Simulation. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of ningde, China (No. 2024J15)..
Abstract (Originalsprache)
Chemoresistance remains a major barrier to effective treatment of gastric cancer (GC), particularly in advanced disease, where cytotoxic chemotherapy often yields limited and transient responses. The present study provides integrated computational and experimental evidence that targeting TLR2 using repurposed small‐molecule inhibitors can overcome autophagy‐dependent chemoresistance in gastric adenocarcinoma cells. A library comprising 1555 FDA‐approved drugs was sourced from the DrugBank database, virtual screening was executed, and two compounds, Nilotinib (DB04868) and Lomitapide (DB08827), achieved affinities ≤ −10 kcal/mol. Chemoresistant GC cells were developed, and experimental assessment was performed using cell proliferation assay, apoptosis assay, real‐time PCR, and western blot analysis. Nilotinib and Lomitapide significantly reduced the proliferation but increased the apoptosis of chemoresistant GC cells. Additionally, Nilotinib and lomitapide reduced the mRNA and protein levels of autophagy‐related factors, LC3B , Beclin‐1 , and p62/SQSTM1 , and activated transcription factors in chemoresistant GC cells. In conclusion, our results suggest that combining TLR2‐targeted agents with standard chemotherapy could be a promising strategy to overcome refractory disease in GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery Zone 2, Ningde Clinical Medical College of Fujian Medical University, Ningde City, Fujian, China.
- Department of Gastrointestinal Surgery, Ningde Municipal Hospital, Ningde City, Fujian, China.
ORCID-Profile: Jin Gao
Förderung
- Natural Science Foundation of ningde, China (No. 2024J15).
Zitieren
APA
Zheng, K., Lei, X., Lin, B., Yang, Q., He, C., Gao, J., & Li, F. (2026). Targeting TLR2 to Overcome Autophagy‐Dependent Chemoresistance in Gastric Cancer: Integrating Molecular Docking, Mechanistic Validation, and Therapeutic Evaluation. Journal of Biochemical and Molecular Toxicology, 40(11). https://doi.org/10.1002/jbt.71137
Vancouver
Zheng K, Lei X, Lin B, Yang Q, He C, Gao J, et al. Targeting TLR2 to Overcome Autophagy‐Dependent Chemoresistance in Gastric Cancer: Integrating Molecular Docking, Mechanistic Validation, and Therapeutic Evaluation. Journal of Biochemical and Molecular Toxicology. 2026;40(11). doi:10.1002/jbt.71137
BibTeX
@article{Zheng2026,
author = {Zheng, Kuanheng and Lei, Xinjian and Lin, Bin and Yang, Qianhong and He, Cong and Gao, Jin and Li, Feng},
title = {Targeting TLR2 to Overcome Autophagy‐Dependent Chemoresistance in Gastric Cancer: Integrating Molecular Docking, Mechanistic Validation, and Therapeutic Evaluation},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
volume = {40},
number = {11},
doi = {10.1002/jbt.71137}
}
EUVIMED